NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Multiple Myeloma, Lymphoma, Leukemia
NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Acute Leukemia, Diffuse Large B-Cell Lymphoma and Multiple Myeloma
NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Acute Leukemia, Diffuse Large B-Cell Lymphoma and Multiple Myeloma
A Phase1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral irreversible menin inhibitor, in adult patients with acute leukemia, diffuse large B-cell lymphoma, and multiple myeloma
Sponsor
Multiple Locations
ClinicalTrials.gov Identifier: NCT05153330
Official Title: COVALENT-101: A Phase1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Irreversible Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), and Multiple Myeloma (MM)
First Posted : December 10, 2021
Click here to see details on ClinicalTrials.gov
Drug: BMF-219
Menin Inhibitor BMF-219 (Code C185864)
BMF 219
BMF-219
BMF219
Menin Inhibitor BMF-219
Menin-MLL Interaction Inhibitor BMF-219
Locations
United States, California
United States, Florida
United States, Ohio
United States, Tennessee
United States, Texas